BACKGROUND: Combination antiretroviral therapy (cART) may vary in ability to suppress viral load and increase CD4+ T-cell count in people infected with different HIV-1 subtypes, possibly due to differences in resistance development. Antiretroviral drugs have predominantly been developed in Western Europe/North America on the basis of the most prevalent subtype, B. However, non-B subtypes are increasingly spreading worldwide. OBJECTIVE: To compare virological and immunological response to cART between patients infected with B and non-B subtypes across Europe. DESIGN: EuroSIDA prospective, observational cohort with 11,928 HIV-1-infected patients. METHODS: Response to cART was analysed in patients with subtypes determined pre-cART, via multivariable logistic regression on the first measurements 6-12 months after starting cART. A virological response was defined as a viral load <500 copies/mi and immunological response as a CD4+ T-cell count increase of > or =100 cells/mm(3). RESULTS: Forty-five percent of patients were antiretroviral naive at initiation of cART. Virological suppression was achieved by 58% of 689 subtype-B-infected patients and 66% of 102 non-B-infected patients (P=0.159). After adjustment for potential confounders, there was no significant difference in odds of achieving virological suppression (non-B compared with B; odds ratio [OR]: 1.05, 95% confidence interval [CI]: 0.58-1.93, P=0.866). An immunological response was achieved by 43% of 753 B-infected patients and 48% of 114 non-B-infected patients (P=0.334). After adjustment, there was no significant difference in odds of an immunological response (OR: 1.17, 95% CI: 0.73-1.87, P=0.524). CONCLUSIONS: There was no evidence of significant differences in virological or immunological response to cART between patients infected with HIV-1 B and non-B subtypes.
BACKGROUND: Combination antiretroviral therapy (cART) may vary in ability to suppress viral load and increase CD4+ T-cell count in people infected with different HIV-1 subtypes, possibly due to differences in resistance development. Antiretroviral drugs have predominantly been developed in Western Europe/North America on the basis of the most prevalent subtype, B. However, non-B subtypes are increasingly spreading worldwide. OBJECTIVE: To compare virological and immunological response to cART between patients infected with B and non-B subtypes across Europe. DESIGN: EuroSIDA prospective, observational cohort with 11,928 HIV-1-infectedpatients. METHODS: Response to cART was analysed in patients with subtypes determined pre-cART, via multivariable logistic regression on the first measurements 6-12 months after starting cART. A virological response was defined as a viral load <500 copies/mi and immunological response as a CD4+ T-cell count increase of > or =100 cells/mm(3). RESULTS: Forty-five percent of patients were antiretroviral naive at initiation of cART. Virological suppression was achieved by 58% of 689 subtype-B-infected patients and 66% of 102 non-B-infected patients (P=0.159). After adjustment for potential confounders, there was no significant difference in odds of achieving virological suppression (non-B compared with B; odds ratio [OR]: 1.05, 95% confidence interval [CI]: 0.58-1.93, P=0.866). An immunological response was achieved by 43% of 753 B-infected patients and 48% of 114 non-B-infected patients (P=0.334). After adjustment, there was no significant difference in odds of an immunological response (OR: 1.17, 95% CI: 0.73-1.87, P=0.524). CONCLUSIONS: There was no evidence of significant differences in virological or immunological response to cART between patients infected with HIV-1 B and non-B subtypes.
Authors: Martin Stürmer; Christoph Stephan; Peter Gute; Gaby Knecht; Markus Bickel; Hans-Reinhard Brodt; Hans W Doerr; Lutz Gürtler; Pierre Lecocq; Margriet van Houtte Journal: Antimicrob Agents Chemother Date: 2011-08-08 Impact factor: 5.191
Authors: Krista Delviks-Frankenberry; Andrea Galli; Olga Nikolaitchik; Helene Mens; Vinay K Pathak; Wei-Shau Hu Journal: Viruses Date: 2011-09-09 Impact factor: 5.818
Authors: Ana B Abecasis; Annemarie M J Wensing; Dimitris Paraskevis; Jurgen Vercauteren; Kristof Theys; David A M C Van de Vijver; Jan Albert; Birgitta Asjö; Claudia Balotta; Danail Beshkov; Ricardo J Camacho; Bonaventura Clotet; Cillian De Gascun; Algis Griskevicius; Zehava Grossman; Osamah Hamouda; Andrzej Horban; Tatjana Kolupajeva; Klaus Korn; Leon G Kostrikis; Claudia Kücherer; Kirsi Liitsola; Marek Linka; Claus Nielsen; Dan Otelea; Roger Paredes; Mario Poljak; Elisabeth Puchhammer-Stöckl; Jean-Claude Schmit; Anders Sönnerborg; Danika Stanekova; Maja Stanojevic; Daniel Struck; Charles A B Boucher; Anne-Mieke Vandamme Journal: Retrovirology Date: 2013-01-14 Impact factor: 4.602
Authors: Osnat Penn; Adi Stern; Nimrod D Rubinstein; Julien Dutheil; Eran Bacharach; Nicolas Galtier; Tal Pupko Journal: PLoS Comput Biol Date: 2008-11-07 Impact factor: 4.475